Recursion Pharma Director Gets $335K Stock Grant Package in Annual Compensation

Recursion Pharmaceuticals (RXRX) Director Robert Hershberg received new equity compensation grants on June 18, 2025.

Rhea-AI Filing Summary

Recursion Pharmaceuticals (RXRX) Director Robert Hershberg received new equity compensation grants on June 18, 2025. The awards consist of:

• 22,016 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
• Stock options to purchase 44,031 shares at an exercise price of $5.11 per share, vesting on the same schedule as the RSUs

Following these transactions, Hershberg directly owns 73,732 shares of Class A Common Stock and 44,031 stock options. These equity grants were made automatically under the company's Outside Director Compensation Policy and are subject to continued service requirements. The filing indicates standard insider trading reporting compliance under Section 16(a) of the Securities Exchange Act.

Insider Trade Summary

Grant/Award: 66,047 shares

Grant/Award 2 txns

Insider HERSHBERG ROBERT

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	44,031	$0.00	$0.00
Grant/Award	Class A Common Stock	22,016	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 44,031 contracts (Direct); Class A Common Stock — 73,732 shares (Direct)

Footnotes (2)

1. F1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.
2. F2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider trading activity occurred at RXRX on June 18, 2025?

Director Robert Hershberg received two equity grants: 22,016 restricted stock units (RSUs) and stock options to purchase 44,031 shares of Class A Common Stock at an exercise price of $5.11 per share.

When do Robert Hershberg's RXRX stock options and RSUs vest?

Both the RSUs and stock options will vest on the earlier of June 18, 2026, or the day prior to Recursion Pharmaceuticals' 2026 Annual Meeting of Stockholders, subject to Hershberg's continued service to the company.

How many RXRX shares does Robert Hershberg own after the June 2025 grants?

Following the transactions, Robert Hershberg directly owns 73,732 shares of Class A Common Stock and 44,031 stock options. The RSUs and options were granted at $0 cost as part of the company's Outside Director Compensation Policy.

What is the exercise price and expiration date of RXRX stock options granted to Hershberg?

The stock options were granted with an exercise price of $5.11 per share and expire on June 18, 2035, ten years from the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2025 - 05:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HERSHBERG ROBERT

(Last) (First) (Middle)

C/O RECURSION PHARMACEUTICALS

41 S. RIO GRANDE STREET

(Street)

SALT LAKE CITY UT 84101

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RECURSION PHARMACEUTICALS, INC. [ RXRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/18/2025		A(1)		22,016	A	$0	73,732	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$5.11	06/18/2025		A		44,031		(2)	06/18/2035	Class A Common Stock	44,031	$0	44,031	D

Explanation of Responses:

1. Represents a grant of restricted stock units automatically granted pursuant to the Issuer's Outside Director Compensation Policy. The restricted stock units will vest on the earlier of June 18, 2026 or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

2. The shares subject to this option will vest and become exercisable on the earlier of June 18, 2026 or the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continued service to the Issuer.

Remarks:

	/s/ Jonathan Golightly, attorney-in-fact	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.